Cancer Center, the Division of
Hematology/Oncology and the Cancer
Research Institute at Scott & White
Healthcare; professor of medicine, Texas
A&M Health Science Center College of
Medicine; and the Stone Centennial
Endowed Chair in Cancer Research.
In addition, through partnerships with
the National Cancer Institute (NCI) and
seven other research groups, Scott & White
participates in more than 150 clinical trials
that involve thousands of cancer patients
nationwide. With scientists who develop
and test drugs and physicians who conduct
clinical trials in the same place, advances in
research and treatment can be accelerated.
This unique concept is what cements the
Cancer Research Institute leadership.
“Without this system,” Dr. Frankel says,
“it would probably take much longer and
be many times more expensive to bring
new treatments to people who need them,
especially those with rare forms of cancer.”
Dr. Frankel has been studying cancer
since the late 1970s, when he was a
research scientist at the National Institutes
of Health (NIH). He believes the
combined expertise of basic science
research and translational medicine—
including clinical trials—at Scott & White
can help thousands of cancer patients and
ultimately bring more patients outside
Central Texas to Scott & White. That was
part of the vision for the Scott & White
Cancer Research Institute when Dr.
Frankel and his team of researchers were
“The Scott & White Cancer Research Institute
is one of few non-profit institutions doing
drug development. We synthesize new drugs
in our laboratory and take them